AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01138410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCIB1
Description: Aqueous solution of plasmid DNA administered by intramuscular injection using the TDS-IM electroporation device (Ichor Medical Systems, Inc.) at week 0, 3, 6, 12 and 24. Part 1 of the study will escalate through 0.4, 2.0, 4.0 and 8.0 mg dose level cohorts, each of three patients. In Part 2 of the study the 4.0 and 8.0 mg doses will be administered in the same regimen. At the discretion of the investigator, patients in both parts of the study may continue to receive SCIB1 at 3-6 month intervals for 5 years.
Study NCT01657305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleogel-S10, non-adhesive wound dressing
Description: 1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
Study NCT01657305 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-adhesive wound dressing only
Description: Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
Study NCT02522468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wire Localization
Study NCT01673516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The SymplicityTM Renal Denervation System
Description: For patients who will be randomly assigned to undergo renal denervation (group RDN), the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Simplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
Study NCT01673516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The HOTMAN® System
Description: Impedance Cardiography by HOTMAN system will evaluates non-invasively hemodynamic parameters in patients randomized to group Co
Study NCT02259114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birabresib
Description: Birabresib 10, 20 and/or 40 mg oral capsules
Study NCT00658268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clodronate
Description: 60 mg/ml, 10 ml, single dose mixed in bone graft at operation
Study NCT00658268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 ml, single dose mixed in bone graft at operation
Study NCT04734132 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa
Description: Leaves of Moringa oleifera from an organic Iberian peninsula cultivar. A single lot was prepared from the same crop. Leaves were dried and ground and encapsulated as a organic dietary supplement. No other changes in diet or physical activity were included although a general healthy lifestyle pattern was recommended.
Study NCT04734132 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules were indistinguishable from the experimental capsules in material and color (opaque white). Same number of capsules were consumed as in the experimental arm and no other changes in diet or physical activity were included although a general healthy lifestyle pattern was recommended.
Study NCT03920891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon Pulmonary Vein isolation
Description: 1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm second or third cryoballoon catheter will be used.~4. Esophageal temperature will be monitored to prevent esophageal injury.~5. Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~6. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~7. The procedure and cryoablation times will be evaluated.~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.
Study NCT03920891 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation
Description: 1. Pulmonary vein isolation will be performed using a radiofrequency catheter.~2. Additional left atrium posterior wall isolation, left atrium anterior wall linear ablation, cavo-tricuspid isthmus ablation, superior vena cava-right atrial septal ablation.~3. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~4. Evaluated the procedure and radiofrequency ablation time.~5. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.
Study NCT00699101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conture Multi-Lumen Balloon
Description: Placement of the balloon in a separate procedure using ultrasound guidance after surgery for breast cancer.
Study NCT01564342 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: wound irrigation with study fluid
Description: wounds were either irrigated with sterile normal saline or tap water.
Study NCT00938301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04455242
Description: Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.
Study NCT00938301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PIC matching in appearance to PF-04455242 will be used to administer placebo.
Study NCT02842593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower-repetition, heavier-load
Description: 8-12 reps/set at \~80% 1 repetition maximum
Study NCT01098838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161
Study NCT03751592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorogenic acid
Description: Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
Study NCT04473144 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ulinastatin
Description: In the Ulistine administration group, 300,000 KIU was mixed with 100 mL physiological saline and administered over 15 minutes after induction of anesthesia.
Study NCT02553161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Youth in the MED condition will be given the USFDA approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks. Titration will be no faster than 5mg/week. This titration guideline was drawn from the escitalopram package insert for pediatric dosing, which states that target doses may be achieved by 4 weeks.
Study NCT02553161 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive behavioral Psychotherapy
Description: All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
Study NCT02842593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Higher-repetition, lighter-load
Description: 20-25 reps/set at \~30% 1 repetition maximum
Study NCT06098326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, fludarabine, and antithymocyte globulin
Description: 1. Cyclophosphamide 50 mg/kg/day i.v. daily on days -3 and -2 (for 2 days)~2. Fludarabine 30 mg/m2/day i.v. daily on days -7to -2 (for 6 days)~3. Antithymocyte globulin (Thymoglobulin) 1.5 mg/kg/day (for HLA-matched sibling donor HCT) or 3.0 mg/kg/day (for other alternative donor HCT) i.v. daily on days -3 to -1 (for 3 days)
Study NCT02382588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gancyclovir gel
Description: 0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
Study NCT02382588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hypromellose gel
Description: 0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
Study NCT06033625 — intervention group
Intervention type: PROCEDURE
Intervention: CEMENTLESS TOTAL KNEE REPLACEMENT
Description: CEMENTLESS CRUCIATE RETAINING BICOMPARTMENTAL TOTAL KNEE REPLACEMENT
Study NCT00168519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroprusside, pentalong, imdur, AICAR, isoptin
Description: Sodium Nitroprusside - one 30 minute intravenous infusion~Pentalong - two tablets orally (total 160mg)~Imdur - two tablets orally (total 120mg)
Study NCT01405807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab will be administered on Day 1 and Day 2 at 0 and 6 months
Study NCT03352596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low frutose diet
Study NCT00779870 — intervention group
Intervention type: OTHER
Intervention: bronchoscopy
Description: bronchoscopy under local anaesthetic and sedation to obtain endobronchial biopsies
Study NCT00134069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00134069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT00134069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT02759913 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Collection of biofluids to determine the accuracy, sensitivity and specificity of a diagnostic test developed by Iron Horse Diagnostics
Study NCT00546481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]
Description: 0.6 micrograms/kg every 2 weeks
Study NCT02086097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol
Description: 25m of dexketoprofen (oral intake) every 8 hours
Study NCT01476384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose drink: 75 gram dextrose monohydrate, dissolved in 250 ml water
Study NCT02086097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 600 mg of Ibuprofen (Oral Intake) every 8 hours
Study NCT02086097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: INACTIVE SUGAR PILLS
Study NCT00525486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine extended release
Description: Nifedipine extended release PO 30 mg X2/d until 34 weeks' gestation
Study NCT01149369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
Study NCT01149369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
Study NCT01134237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: urokinase
Description: intrapleural urokinase injection
Study NCT01134237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal saline as a placebo for control arm
Study NCT04071756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Tazarotene
Description: This medicine works by making the skin less inflamed and reducing the thickness and pain from lesions of the skin
Study NCT04071756 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance that has no therapeutic effect, used as a control in testing new drugs
Study NCT02568644 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extract of ginger
Description: People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols).
Study NCT02568644 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose).
Study NCT02568644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous ketoprofen
Description: People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).
Study NCT02568644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen
Description: People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).
Study NCT02275377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Description: Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 40% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 40% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
Study NCT02275377 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham IMT
Description: Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
Study NCT02298452 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hearing aid.
Description: The hearing aid will be fitted to the individual hearing loss of the subject.
Study NCT03298724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teachers and Parents as Partners
Description: A family-school partnership intervention to improve the home-school connection, parenting and teaching strategies, and child behavior outcomes.
Study NCT00203216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Description: Daily dose of open label levatiracetam was 3000 mg. or maximally tolerated dose. (Maximum daily dose: 3000 mg. Minimum daily dose allowed for study participation:1000 mg)
Study NCT00203216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Study NCT02459782 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound guided Dual Quadrant Peribulbar Anaesthesia
Description: Landmark Guided single injection vs Ultrasound guided dual quadrant injection
Study NCT04447482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENB with image-guided lung biopsy
Description: Electromagnetic navigational bronchoscopy system with tip tracked instruments.
Study NCT04447482 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Bronchoscopy guided by Fluoroscopy
Description: Bronchoscopic lung biopsy with fluoroscopy.
Study NCT05661994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation
Description: Patients with CAD were divided into the Omega-3 Group (n:16) and Control Group (n:18) to evaluate the effects of omega-3 FA supplementation on biochemical parameters, especially serum fetuin-A, anthropometric measurements, and nutritional status. 1.560 mg/day omega-3 FA supplementation was applied for 8 weeks to 16 participants with CAD included in the omega-3 group.
Study NCT01476384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 ml water
Study NCT00987012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Description: Twice daily ingestion of pomegranate juice over 4-5 days
Study NCT00987012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Twice daily ingestion of placebo drink over 4-5 days
Study NCT00757926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV]
Description: Three oral doses of the vaccine (0.5 ml each) following oral administration of antacid.
Study NCT00757926 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three oral doses of the placebo (0.5 ml each)following oral administration of antacid.
Study NCT04398199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: The prescribed dose will be 70 Gy in 25 fractions. Participants will radiation therapy once a day for 25 days, Monday through Friday (around 5 weeks).
Study NCT04398199 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Boost
Description: Undergo simultaneous integrated boost (SIB) to treat both planned target volumes with daily image guidance. This approach allows daily confirmation of target localization and simultaneous delivery of lower dose per fraction to low risk areas while maintaining a high dose per fraction to the highest risk areas.
Study NCT01562704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol (drug)
Description: The objective of this study is to evaluate the mechanism of action of paracetamol (versus placebo) in the brain with new assessment tools (functional MRI and test inducing pain by thermal stimulation
Study NCT03195075 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasonography guided biliary drainage
Description: Endoscopic ultrasonography guided biliary drainage includes rendezvous techniques, endoscopic ultrasonography guided choledochoduodenostomy, and endoscopic ultrasonography-guided hepatogastrostomy using self-expandable metal stent will be done for group 1
Study NCT03195075 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous trans-hepatic biliary drainage
Description: Percutaneous trans-hepatic biliary drainage in interventional radiology department using self-expandable metal stent will be done for group 2
Study NCT03000842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagal nerve stimulation on
Description: electrical current on positioned in the ear to estimate vagal branch of auricular nerve
Study NCT03000842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagal nerve stimulation off
Description: an electrical current off positioned in the ear to estimate vagal branch of auricular nerve
Study NCT03999034 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: questionnaire completion
Description: Every patient (140) and healthy control (400) will fill in all the tests and questionnaires, except FSS, in a random order during a single appointment. The FSS will be fill in by patients only. All 400 healthy controls will be divided in 20 groups of 20 people, according to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not). 60 of them will pass the XO test at the beginning and again at the end of the consult to investigate the test-retest effect.
Study NCT02288624 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Processed orange juice
Description: 3 different formulation of edible orange drinks
Study NCT02288624 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Processed orange juice
Description: 3 different formulation of edible orange drinks
Study NCT00546481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin
Description: As prescribed, iv, 3 times weekly
Study NCT03576235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG102P
Description: Daily dose of 1.5g
Study NCT02010944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate
Description: oral
Study NCT02010944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral
Study NCT02010944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron/solifenacin succinate
Description: oral
Study NCT03576235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of placebo